Ocular Hypertension & Glaucoma Suspect

Overview

Ocular hypertension (OHT) is intraocular pressure (IOP) above the statistically normal range (conventionally >21 mmHg) in the absence of glaucomatous optic nerve damage or visual field loss. "Glaucoma suspect" is a broader category that also includes patients with suspicious optic disc features, asymmetric cup-disc ratios, or other risk factors even at normal IOP. Both represent a spectrum of risk rather than a diagnosis of glaucoma itself, and management hinges on individualized risk stratification.

Epidemiology & Risk Factors

OHT is common, and only a minority of patients will ever develop glaucoma. In a large UK electronic-health-record cohort of over 9,000 OHT patients followed for 5 years, 16.9% converted to glaucoma.² The landmark Ocular Hypertension Treatment Study (OHTS) identified the major risk factors for conversion: older age, higher IOP, larger cup-disc ratio, higher visual field pattern standard deviation, and thinner central corneal thickness (CCT).¹ In a managed-care pilot study, known risk factors were present in roughly one third of patients, and age, mean CCT, and cup-disc ratio were significant predictors of visual field mean deviation, while diabetes mellitus was observed to have a protective association.³

Pathophysiology

Elevated IOP reflects an imbalance between aqueous humor production and outflow resistance, typically at the trabecular meshwork. Whether elevated IOP alone causes clinically significant glaucomatous optic neuropathy in a given individual depends on additional factors, including corneal biomechanics (thinner CCT is associated with underestimated true IOP on applanation tonometry and independently predicts conversion), optic nerve structural vulnerability, and possibly vascular factors — explaining why some patients tolerate elevated IOP indefinitely while others develop damage at statistically "normal" pressures (see Normal-Tension Glaucoma).

Clinical Presentation

OHT and glaucoma suspect status are virtually always asymptomatic, identified incidentally on routine eye exams via elevated IOP measurement, an anomalous-appearing optic disc, or a family history prompting screening. There are no symptoms to guide diagnosis, making objective testing essential.

Exam Findings

• Elevated IOP (typically >21 mmHg) without glaucomatous cupping
• Normal, stable visual fields on formal perimetry
• Normal retinal nerve fiber layer (RNFL) on OCT, or a "suspicious" but non-diagnostic disc appearance (e.g., mild asymmetry, focal thinning) prompting closer surveillance
• Central corneal thickness measurement, since thinner CCT both affects IOP measurement accuracy and independently predicts risk

Differential Diagnosis

• Early primary open-angle glaucoma (established optic nerve/visual field damage, distinguishing it from OHT)
• Normal-tension glaucoma (glaucomatous damage at statistically normal IOP — the converse scenario)
• Physiologically large but stable/non-progressive cup-disc ratio ("physiologic cupping")
• Secondary causes of elevated IOP (steroid response, pigmentary or pseudoexfoliative glaucoma, uveitic glaucoma) that should be excluded before labeling a patient as primary OHT

Management

Risk stratification is central to management. The OHTS risk calculator (based on age, IOP, CCT, cup-disc ratio, and visual field pattern standard deviation) helps estimate an individual's 5-year conversion risk to glaucoma, and updated/externally validated versions of this model continue to show useful, if modest, predictive discrimination in contemporary cohorts.² OHTS demonstrated that treating OHT with topical IOP-lowering medication reduces the 5-year conversion rate to glaucoma to less than half that of untreated, monitored patients.¹

Management is therefore individualized: patients at higher calculated risk (particularly those with multiple risk factors — older age, higher IOP, thin CCT, larger cup-disc ratio, or suspicious visual field indices) are generally offered treatment, while lower-risk patients may reasonably be monitored without treatment, with regular follow-up including IOP checks, disc/RNFL imaging, and visual field testing to detect any conversion early.

Complications

• Progression to manifest glaucoma with optic nerve damage and visual field loss if unrecognized or undertreated in higher-risk patients
• Unnecessary treatment burden (cost, side effects, adherence challenges) in lower-risk patients who are unlikely to ever develop glaucoma
• Under- or over-estimation of true IOP in patients with abnormal CCT if this is not accounted for in risk assessment

Clinical Pearls

• Roughly 1 in 6 OHT patients converts to glaucoma over 5 years in real-world data — most do not, supporting individualized rather than universal treatment²
• Treating OHT roughly halves the 5-year conversion rate to glaucoma compared with observation alone — this is the central, practice-changing finding of OHTS¹
• Thinner central corneal thickness is both a source of IOP measurement error and an independent risk factor for conversion — always measure CCT in OHT/glaucoma suspect patients¹
• Risk calculators are useful but imperfect (modest discriminative ability even after refinement) — use them to inform, not replace, clinical judgment²
• Always exclude secondary causes of elevated IOP (steroid use, pigment dispersion, pseudoexfoliation) before treating as primary OHT

Common Pitfalls

• Treating all patients with elevated IOP uniformly without individualized risk assessment
• Failing to measure central corneal thickness, leading to both measurement error and missed risk stratification
• Assuming any patient with normal fields and stable disc but elevated IOP requires no follow-up — periodic monitoring remains essential even in untreated, lower-risk patients
• Overlooking secondary/reversible causes of elevated IOP (e.g., topical or systemic steroid use) that would change management
• Mistaking physiologic large cup-disc ratio for a glaucoma suspect finding without considering family history, symmetry, and stability over time